Background. Treatment with nucleos(t)ide analogues (NA) suppresses hepatitis B virus (HBV) DNA but rarely leads to functional cure of chronic hepatitis B (CHB). Following NA cessation, some hepatitis B e antigen (HBeAg)-negative CHB patients experience hepatitis B s antigen (HBsAg) loss. Cellular immune responses, including natural killer (NK) cell responses, explaining virological events following NA treatment cessation remain elusive.
Treatment of chronic hepatitis B (CHB) includes pegylated interferon-alfa (peg-IFN-α) and oral antiviral agents such as nucleos(t)ide analogues (NAs) [1, 2] . NAs, which represent the main treatment option, are effective in almost all patients and ameliorate development of liver fibrosis [1] . However, functional cure (ie, hepatitis B s antigen [HBsAg] loss) is a rare event because these drugs have limited effect on covalently closed circular DNA [1, 2] . Accordingly, NA treatment is currently given for very long, often indefinite, periods of time [1, 2] . This is in particular the case for hepatitis B e antigen (HBeAg)-negative CHB patients [1] .
Consequently, a number of studies have recently evaluated if stopping NA treatment before loss of HBsAg is clinically feasible in HBeAg-negative CHB patients [3] [4] [5] . Although cessation of NA treatment often leads to recurrence of hepatitis B virus (HBV) DNA, the procedure appears safe and was recently introduced into the European Association for the Study of the Liver (EASL) guidelines as a recommendation in selected HBeAg-negative CHB patients [1, [3] [4] [5] . In a landmark paper by Hadziyannis and colleagues [6] , more than a third of patients achieved HBsAg loss at long-term follow-up after structured NA cessation. Intriguingly, following HBV DNA recurrence, a majority of patients also experienced alanine aminotransferase (ALT) flares [6] . Thus, it is possible that the functional cure observed after NA cessation was due to elimination of HBVinfected hepatocytes by immune cells. In relation to this, it has been shown that activation of natural killer (NK) cells, innate effector lymphocytes specifically enriched in the human liver [7] , coincides with hepatic flares in CHB [8] . Furthermore, we recently reported that cessation of NA treatment is associated with potent induction of inflammatory and antiviral cytokines [9] . However, cellular immunological responses connected to the virological and clinical events that develop after NA cessation in CHB remain unclear.
NK cells are important mediators of antiviral immune responses. They can recognize and eliminate infected cells via natural cytotoxicity and other mechanisms [10, 11] . NK cells have previously been studied to some extent in the context of CHB [12] [13] [14] [15] , where they have been shown to exacerbate liver damage [8, 16, 17] . Recent work has also revealed NK cells to act as rheostats in modulating immunopathology [18] by targeting of HBV-specific T cells [19, 20] . In the present study, we hypothesized that NK cells would partake in the immune response developing following cessation of NA treatment in CHB.
To investigate this, NK cells were longitudinally assessed in HBeAg-negative CHB patients undergoing structured NA cessation. Using an unsupervised high-dimensional analysis approach, we show that CHB causes a significant imprint on the NK cell compartment, whereas stopping NA treatment only resulted in minor phenotypic changes. Intriguingly, an observed augmented NK cell natural cytotoxicity response following stopping NA treatment coincided with CHB patients experiencing ALT flares, suggesting NK cell-mediated cytotoxicity against HBV-infected hepatocytes. This was particularly evident in patients achieving HBsAg seroclearance at long-term follow-up. Taken together, our results provide insights into events occurring within the NK cell compartment following structured NA cessation in CHB and suggest a role for NK cells in achieving HBsAg seroclearance.
MATERIAL AND METHODS

Study Design
Fifteen HBeAg-negative CHB patients were recruited in a prospective trial ( Figure 1A ). The HBV genotype distribution was 3, 1, and 10 for genotypes B, C, and D, respectively (genotype not available for 1 patient). At treatment cessation, the mean ALT value was 31 U/L (range: 12-61 U/L), the FibroScan 6.7 kPa (range: 2.3-11.4 kPa), and the mean HBsAg level 1343 IU/ mL (range: 17-3674 IU/mL). The specific inclusion and exclusion criteria as well as more detailed clinical characteristics have previously been reported [9] .
Human Peripheral Blood Mononuclear Cells and Cell Lines
Blood was collected at the time of NA cessation (stop) as well as at weeks 4, 8, and 12 after cessation. For 2 CHB patients, blood from week 2 and week 24 after NA cessation was grouped with stop and week 12, respectively. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll Hypaque density gradient centrifugation and cryopreserved in liquid nitrogen for later analysis. The cell lines K562 and 721.221 (both from ATCC) were kept in complete RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% fetal calf serum (Thermo Fisher Scientific) and 1 mM l-glutamin (Invitrogen).
Flow Cytometry
Cryopreserved PBMCs were stained with fluorescently labeled antibodies (Supplementary Table 1 ). Staining was performed as previously described [21] . Samples were acquired on a 20-parameter 5-laser BD LSR Fortessa (BD Biosciences).
Functional NK Cell Assays
Cryopreserved PBMCs were thawed and either rested or prestimulated overnight with interleukin-12 (IL-12; 10 ng/mL; PeproTech) and IL-18 (100 ng/mL; R&D Systems) at 37°C and 5% CO 2 . After overnight incubation, target cells were added at a 10:1 effector to target ratio for an additional 6 hours. To access antibody-dependent cellular cytotoxicity (ADCC), rituximab (1 μg/mL) was added to the 721.221 cells. Anti-CD107a fluorescein isothiocyanate (FITC; BD Biosciences) was present throughout the final 6 hours of the assay and monensin as well as brefeldin A (BD Biosciences) for the final 5 hours. PBMCs were subsequently stained and analyzed with flow cytometry as described above.
Conventional and High-Dimensional Analysis of Flow Cytometry Data
Obtained data were analyzed by conventional flow cytometry analysis using FlowJo. Spice (provided by Mario Roederer and Joshua Nozzi, National Institutes of Health) was used for postprocessing of functional data. For high-dimensional analysis of flow cytometry data, stochastic neighbor embedding analysis (SNE), was performed using R as previously described [21] . R and the package corrplot were used to create correlation matrices.
Statistics
Data were analyzed using Graph Pad Prism. All data were tested for normality using the D´Agostino-Pearson omnibus normality test. Statistical significance was, for normally distributed data, assessed using paired or nonpaired student t test. For nonnormally distributed data, Wilcoxon matched pairs signed rank test was used for matched pairs of data or Mann-Whitney test when data were unmatched.
Ethical Approval
The study protocol conforms to the 1975 Declaration of Helsinki and the ethics committee of Hannover Medical School reviewed the project. All patients gave written informed consent to participate in the study.
RESULTS
Clinical Outcome and Overall NK Cell Response
The virological outcome of the cohort has previously been published in detail [9] . Relevant to this study on NK cell responses are that 13 out of 15 patients experienced a rapid virological relapse detectable as early as 4 weeks after stopping NA treatment. This was commonly followed by biochemical relapse within the first 12 weeks after treatment cessation ( Figure 1B ). During shortterm follow-up, HBsAg levels were stable ( Figure 1B) . As previously reported, 3 patients went on to clear HBsAg after long-term follow-up [9] . For most CHB patients, NA treatment was reintroduced at week 12 [9] . Long-term NA treatment of CHB had no impact on peripheral blood NK cell frequencies compared to healthy controls ( Figure 1C and 1D) . When NK cells were monitored following the termination of NA treatment, stable frequencies of total NK cells as well as of CD56 dim and CD56 bright NK cell subsets were noted ( Figure 1D ). This was also observed for the subgroup of patients that went on to clear HBsAg at longterm follow-up. We recently reported that NA cessation in CHB Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; DCM, dead-cell marker; FSC, forward scatter; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-gamma; ns, not significant; PBMC, peripheral blood mononuclear cells; SNE, stochastic neighbor embedding; SSC, side scatter. *** P < .001, ** P < .01.
is associated with potent induction of inflammatory and antiviral cytokines in circulation [9] . This robust cytokine activation stands in contrast to the stable frequencies of NK cells we observed in our study. This prompted us to next perform an in-depth characterization of the NK cell population, the major innate immune effector subset responding in CHB.
High-Dimensional SNE Analysis Reveals Stable Imprint of CHB on the NK Cell Compartment
Before assessing the NK cell response following cessation of NA treatment, we first analyzed the impact on the NK cell compartment in CHB patients that had been on long-term NA treatment.
A recent meta-analysis of the NK cell response in CHB revealed a degree of heterogeneity between published studies [22] . This encouraged us to take an unsupervised high-dimensional analysis approach. Fourteen activating and inhibitory receptors, as well as activation and differentiation markers, were simultaneously assessed on NK cells at the single-cell level ( Figure 2A ). Next, all CHB and healthy control samples were given electronic bar codes, pooled, and subjected to unsupervised SNE analysis. SNE projects high-dimensional data into low-dimensional space and has been shown to be superior compared to other dimensionality reduction techniques for flow cytometry data analysis [21, 23] . Subsequently, the single-cell data were deconvoluted and SNE maps of NK cells from CHB patients were compared to healthy controls ( Figure 2B ). This showed substantial differences in the NK cell compartment of CHB patients, which could be visualized in a residual map representing clusters of cells that were more or less abundant in CHB patients as compared to controls ( Figure 2B , residual map). In order to interpret the differences in phenotype, we displayed SNE maps for each of the 14 investigated receptors and projected the residual map onto these. This revealed that differences between CHB patients on long-term NA treatment and healthy controls primarily were attributed to lower NK cell expression of CD16, NKG2A, Siglec-7, and NKp30 as well as increased expression of pan-KIRs and CD57 ( Figure 2B ). Importantly, a number of these alterations could be recapitulated via conventional flow cytometry analysis (Supplementary Figure 1) , whereas others were only present in multidimensional space.
Next, we performed pairwise comparisons of NK cellbased SNE maps from the CHB patients at the time of and during NA cessation. Only minor phenotypic alterations were detected following cessation of NA treatment ( Figure 2C ). This finding was corroborated by conventional single-marker analysis ( Figure 2D ). Taken together, unsupervised SNE analysis revealed a robust imprint on the NK cell compartment in peripheral blood by CHB in long-term NA-treated patients. However, NA cessation and the ensuing return of HBV were not associated with major phenotypic changes within the compartment.
NK Cell Natural Cytotoxicity Responses Are Robustly Augmented Following Structured NA Cessation
We next analyzed different aspects of NK cell function. Natural cytotoxicity, ADCC, and functional responses following cytokine stimulation were evaluated and 5 NK cell functions were simultaneously measured within the CD56 dim and CD56 bright NK cell compartments ( Figure 3A and Supplementary Figure 2A) . Before NA cessation, only minor differences in NK cell function were detected, including lower responses to cytokine stimulation within the CD56 dim NK cell compartment ( Figure 3B ). Instead, stopping NA treatment significantly boosted CD56 dim NK cell natural cytotoxicity responses, which started to become apparent at week 8 after cessation but developed even stronger at week 12 ( Figure 3C ). In line with this, significantly more NK cells responded with 2 or 3 functions simultaneously following stimulation with K562 or 721.221 cells at week 12 after NA cessation as compared to the stop time-point ( Figure 3D and Supplementary Figure 2B) .
In summary, whereas stopping NA treatment resulted in minor phenotypic alterations within the NK cell compartment, elevated functional natural cytotoxicity responses were observed.
Temporal Association Between Increased NK Cell Natural Cytotoxicity
Responses, Liver Damage Following NA Cessation, and HBsAg
Seroclearance
Next , we set out to explore potential correlates between the alterations in NK cell phenotype and function and the virological and biochemical events that transpired after structured NA cessation ( Figure 4 and Supplementary Figure 3) . We observed positive correlations between CD56 dim NK cell responses towards K562 cells and ALT levels at weeks 8 and 12 after treatment cessation (Figure 4 ). Of note, only very few other positive correlations were found between the clinical parameters and other functional readouts at the studied time points as well as between the NK cell phenotypic markers and the clinical parameters ( Figure 4 and Supplementary Figure 3) .
Next, we evaluated the association between elevated ALT levels and increased NK cell functionality after treatment cessation in relation to HBsAg seroclearance. As previously described, the subgroup of CHB patients that went on to clear HBsAg at long-term follow-up experienced higher ALT levels at week 12 after stopping NA treatment as compared to patients that retained HBsAg [9] . Intriguingly, HBsAg seroclearance was also associated with higher CD56 dim NK cell expression of CD38 at week 12 ( Figure 5A ). To assess the functional consequences of increased CD38 expression, the functional capacity of CD56 dim NK cells expressing negative/low, intermediate, or high levels of CD38 was compared. After K562 stimulation, CD38 high NK cells responded with elevated functions as compared to CD38 negative/low NK cells (Supplementary Figure 4) . This was evident both at the stop time point as well as at 12 weeks after NA cessation, suggesting that high CD38 expression, in general, identifies NK cells with high functional capacity (Supplementary Figure 4) . Finally, the functional responses of patients achieving HBsAg seroclearance was compared to patients that retained HBsAg. HBsAg seroclearance was associated with elevated responses upon K562 stimulation at week 12 following NA cessation ( Figure 5B ). Of note, CD56 dim NK cell IFN-γ, tumor necrosis factor (TNF), and GM-CSF responses upon K562 stimulation were also the functions that were significantly augmented when the entire cohort was evaluated at week 12 ( Figure 3C ). Functional responses upon other types of stimulations were not associated with HBsAg seroclearance ( Figure 5C and data not shown).
In summary, this temporal association between augmented NK cell functionality and rise in ALT following NA cessation could indicate a contribution of NK cells to the biochemical relapse, which might be associated with subsequent HBsAg loss at long-term follow-up.
DISCUSSION
In recent years, new strategies to move away from indefinite NA treatment in CHB have been evaluated [5] . Apart from the development of novel drug regimens, structured NA cessation represents the most promising strategy for acceleration of HBsAg loss in carefully selected groups of HBeAg-negative CHB patients [3] [4] [5] . Indeed, this was recently introduced into the updated EASL clinical practice guidelines on the management of HBV infection [1] . In this context, it will be important to understand the immunological events that transpire after stopping NA treatment. Our results show that stopping NA treatment did not have a major impact on the NK cell phenotype. Instead, NK cell natural cytotoxicity responses were augmented following NA cessation, particularly in patients who went on to clear HBsAg. These elevated responses exhibited a temporal association with the rise in ALT experienced by the patients and might, thus, suggest a role for NK cells in clearance of HBV.
Previous studies of NK cells in CHB have primarily relied on low-dimensional flow cytometric assessments of NK cells followed by supervised analysis of single receptor expression. Instead, we here performed a high-dimensional investigation of NK cells combined with unsupervised SNE analysis, an analysis optimized for high-dimensional flow cytometric data [21, 23] . This approach has several advantages, including avoiding the bias introduced by conventional gating as well as the ability to find previously unrecognized cellular phenotypes not present in low-dimensional space. Although the patients had been on long-term NA treatment, the data revealed that CHB caused a significant imprint on the NK cell compartment driven by increased expression of pan-KIRs and CD57, as well as by reduced expression of CD16, NKG2A, NKp30, and Siglec-7.
NKG2A, CD57, and KIRs are the main surface receptors used to characterize CD56 dim NK cell differentiation [24] . The profile of CHB patients with lower NKG2A and increased CD57 and pan-KIR expression is compatible with the NK cells being more highly differentiated [24] . In line with our findings, previous studies have reported reduced expression of CD16, NKp30, and Siglec-7 in CHB [25, 26] . A recent meta-analysis of NK cells in CHB instead showed upregulated expression of activating receptors such as natural cytotoxicity receptors (NKp30 and NKp46), NKG2C, and NKG2D in CHB [22] . Since our cohort had been on stable long-term NA treatment, it is plausible that suppression of HBV has had effects on the NK cell compartment, including lowering the expression of activating receptors, as has previously been reported [20] .
Of note, only minor changes in NK cell phenotype were observed following structured NA cessation. For instance, we failed to observe any induction of activation-related markers such as Ki67, CD69, or TRAIL on NK cells. Both CD69 and TRAIL are highly responsive to IFN-α [27, 28] . It has previously been shown that NK cells from treatment-naive CHB patients express elevated levels of TRAIL and Ki67 [20] . Furthermore, the natural flares occurring in these patients are characterized by induction of IFN-α as well as upregulation of CD69 and TRAIL on NK cells [8] . In contrast to this, Tan and colleagues previously assessed inflammatory serum cytokines and TRAIL expression on NK cells in 5 CHB patients stopping NA treatment (4 HBeAg + and 1 anti-HBe + ) [29] . However, during HBV DNA and ALT flares they did not observe induction of IFN-α or upregulation of TRAIL on NK cells. We also did not observe elevated levels of IFN-α or changes in expression of CD69 and TRAIL, indicating that the viral rebound following NA cessation does not evoke a potent IFN-α response. Instead, the response that we detected is more in line with changes in cytokine patterns observed during acute resolving HBV infection [30] . Whereas our data demonstrated a significant impact of CHB on the phenotype of NK cells, the changes in NK cell functionality before NA cessation were more modest. However, a consistent reduction in CD56 dim NK cell responses following cytokine stimulation was present, which is in line with previous literature [25, 31, 32] . In contrast to this, we observed augmented NK cell natural cytotoxicity responses after NA cessation. This profile of a specific augmentation of NK cell natural cytotoxicity is different from what has been observed during peg-IFN-α treatment or in response to natural flares in CHB. Peg-IFN-α primarily yielded upregulation of TRAIL [33, 34] whereas cytokine and degranulation responses instead were reduced [34, 35] . Although less well studied, natural flares also primarily yielded upregulation of TRAIL on NK cells [8, 36] . One explanation for this discrepancy might be that a substantial fraction of patients in our cohort were retreated with NA at the peak of ALT flare. HBsAg seroclearance is the optimal endpoint of treatment for CHB patients [1] . Our patients had relatively low HBsAg levels, which has been shown to be a predictive factor for HBsAg seroclearance [37, 38] . However, HBsAg seroclearance is still a rare clinical event, with an annual clearance rate of 0.33% taking on average more than 50 years to clear HBV [39, 40] . Importantly, a recent prospective study investigating HBsAg seroclearance in more than 5400 CHB patients receiving NA treatment showed that increased ALT was positively associated with HBsAg loss [39] . Three out of 15 patients followed in our cohort went on to clear HBsAg at long-term follow-up and this was associated with high ALT after stopping therapy [9] . Our data revealed that augmented NK cell natural cytotoxicity responses correlated with high ALT at week 12 following NA cessation. HBsAg seroclearance was also associated with higher CD38 expression on CD56 dim NK cells at this time point. In relation to this, we also showed that NK cells expressing high levels of CD38 responded more vigorously to stimulation with target cells compared to NK cells expressing low levels of CD38.
Several limitations of our study have to be considered. First, the subgroup achieving HBsAg seroclearance at long-term follow-up consists of only 3 patients. Thus, conclusions drawn from the subgroup analysis of these patients need to be confirmed in larger studies for higher statistical robustness. However, patient enrollment into this type of prospective clinical trial is challenging because patients might be unwilling to follow the thorough study protocol upon stopping therapy, strict inclusion criteria limit the number of available patients, and for safety concerns upon termination of treatment [41, 42] . Second, our study design did not allow for assessment of NK cell function at late time points, such as when the ALT flare had subsided or when the actual HBsAg seroconversion took place. However, we studied NK cell responses at 4 time points: before, and at weeks 4, 8, and 12 following NA cessation, where weeks 8 and 12 coincided with HBV DNA and ALT peaks respectively. Nevertheless, it will be of interest in future studies to also assess immune cell responses at later time points. Third, we only had the possibility to characterize the response of circulating NK cells and not intrahepatic cells. Although immunological events transpiring within the liver following NA cessation currently remain unclear, HBV is known to affect expression of NK-cell receptor ligands both on hepatocytes [8, 43, 44] and HBV-specific T cells [19, 45] . Thus, following NA cessation, responding NK cells could potentially contribute to both hepatocyte killing and targeting of HBV-specific T cells. Forth, it remains to be shown if the elevated functional NK cell responses we observed towards the prototypic NK cell target cell lines (K562 cells and 721.221 cells) are translatable to more physiological settings, such as HBV-infected primary hepatocytes. Fifth, in the present study we focused on NK cell responses because these cells are known to respond during viral infection and have been shown to play a role in the immunopathogenesis of CHB [12] [13] [14] [15] . However, it is unlikely that these cells exhibit their functions alone. Rather, they operate in concert with other immune cells. For instance, T cell, although being described as exhausted in CHB, are known to contribute to liver damage and cytokine-induced HBV eradication [13, 46, 47] . Indeed, a recent report associated a high magnitude of HBV-specific T-cell responses at baseline with HBV control upon treatment cessation in CHB [48] .
In conclusion, we report that CHB has a significant impact on the NK cell compartment and that structured NA cessation leads to a specific augmentation of NK cell natural cytotoxicity responses. These augmented responses were associated with liver damage as well as with HBsAg seroclearance in the investigated patients. Our findings constitute new potentially predictive factors that will aid the design of future trials aimed at identifying the patients who would benefit from stopping NA treatment.
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